08:21 AM EST, 02/26/2025 (MT Newswires) -- Theratechnologies ( THTX ) on Wednesday said its fourth-quarter net loss widened on higher expenses, but revenue rose.

The company recorded a net loss of US$7.9 million, or US$0.16 per share, compared with a net loss of US$2.8 million, or US$0.08 per share, in the previous corresponding quarter. Theratechnologies ( THTX ) recorded higher expenses in sales, administration and R&D.

Consolidated revenue rose 6.6%, to a record US$25 million. Net sales of Trogarzo, an HIV-1 medication, increased nearly 13%, while Egrifta, also an HIV-related medication, saw net sales advance 4.2%.